A miRNA-Mediated Approach to Dissect the Complexity of Tumor-Initiating Cell Function and Identify miRNA-Targeting Drugs

Anil Belur Nagaraj; Peronne Joseph; Erin Ponting; Yuriy Fedorov; Salendra Singh; Alex Cole; Woncheol Lee; Euisik Yoon; Alessia Baccarini; Peter Scacheri; Ronald Buckanovich; Drew J. Adams; Ronny Drapkin; Brian D. Brown; Analisa DiFeo

doi:10.1016/j.stemcr.2018.12.002

A miRNA-Mediated Approach to Dissect the Complexity of Tumor-Initiating Cell Function and Identify miRNA-Targeting Drugs

Anil Belur Nagaraj, Peronne Joseph, Erin Ponting, Yuriy Fedorov, Salendra Singh, Alex Cole, Woncheol Lee, Euisik Yoon, Alessia Baccarini, Peter Scacheri, Ronald Buckanovich, Drew J. Adams, Ronny Drapkin, Brian D. Brown, Analisa DiFeo

Yonsei Advanced Science Institute

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

In this article, DiFeo and colleagues have utilized a miRNA 3′ UTR biosensor to study tumor-initiating cells in ovarian cancer and develop a high-throughput platform to uncover miRNA-targeting drugs. They have identified miR-181a as a potent driver of tumor initiation, which can be regulated by BET inhibitors, thus introducing a previously unknown biomarker for these drugs.

Original language	English
Pages (from-to)	122-134
Number of pages	13
Journal	Stem Cell Reports
Volume	12
Issue number	1
DOIs	https://doi.org/10.1016/j.stemcr.2018.12.002
Publication status	Published - 2019 Jan 8

Bibliographical note

Funding Information:
We thank Norma C. and Albert I. Geller for their constant support of the Gynecological Cancer Translational Research Program at Case Western Reserve University (A.D.). In addition, we thank Dr. Anirban Mitra for the HEYA8 cells, Dr. Goutham Narla for the MDA-MB-231 and H358 cells, and Dr. Steven Presnell for the miR-181a luciferase promoter. We acknowledge the help from Cytometry & Imaging Microscopy Core Facility and the Athymic Animal and Preclinical Therapeutics Core of the Case Comprehensive Cancer Center ( P30CA043703 ). This work was supported by grants from The National Cancer Institute , R01CA197780 (A.D.), Department of Defense , OC150553 (A.D.), and The Young Scientist Foundation (A.D.).

Funding Information:
We thank Norma C. and Albert I. Geller for their constant support of the Gynecological Cancer Translational Research Program at Case Western Reserve University (A.D.). In addition, we thank Dr. Anirban Mitra for the HEYA8 cells, Dr. Goutham Narla for the MDA-MB-231 and H358 cells, and Dr. Steven Presnell for the miR-181a luciferase promoter. We acknowledge the help from Cytometry & Imaging Microscopy Core Facility and the Athymic Animal and Preclinical Therapeutics Core of the Case Comprehensive Cancer Center (P30CA043703). This work was supported by grants from The National Cancer Institute, R01CA197780 (A.D.), Department of Defense, OC150553 (A.D.), and The Young Scientist Foundation (A.D.).

Publisher Copyright:
© 2018 The Authors

All Science Journal Classification (ASJC) codes

Biochemistry
Genetics
Developmental Biology
Cell Biology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.stemcr.2018.12.002

Cite this

Belur Nagaraj, A., Joseph, P., Ponting, E., Fedorov, Y., Singh, S., Cole, A., Lee, W., Yoon, E., Baccarini, A., Scacheri, P., Buckanovich, R., Adams, D. J., Drapkin, R., Brown, B. D., & DiFeo, A. (2019). A miRNA-Mediated Approach to Dissect the Complexity of Tumor-Initiating Cell Function and Identify miRNA-Targeting Drugs. Stem Cell Reports, 12(1), 122-134. https://doi.org/10.1016/j.stemcr.2018.12.002

@article{db7c9e689bb843b38a4af823f2d63e34,

title = "A miRNA-Mediated Approach to Dissect the Complexity of Tumor-Initiating Cell Function and Identify miRNA-Targeting Drugs",

abstract = "In this article, DiFeo and colleagues have utilized a miRNA 3′ UTR biosensor to study tumor-initiating cells in ovarian cancer and develop a high-throughput platform to uncover miRNA-targeting drugs. They have identified miR-181a as a potent driver of tumor initiation, which can be regulated by BET inhibitors, thus introducing a previously unknown biomarker for these drugs.",

author = "{Belur Nagaraj}, Anil and Peronne Joseph and Erin Ponting and Yuriy Fedorov and Salendra Singh and Alex Cole and Woncheol Lee and Euisik Yoon and Alessia Baccarini and Peter Scacheri and Ronald Buckanovich and Adams, {Drew J.} and Ronny Drapkin and Brown, {Brian D.} and Analisa DiFeo",

note = "Funding Information: We thank Norma C. and Albert I. Geller for their constant support of the Gynecological Cancer Translational Research Program at Case Western Reserve University (A.D.). In addition, we thank Dr. Anirban Mitra for the HEYA8 cells, Dr. Goutham Narla for the MDA-MB-231 and H358 cells, and Dr. Steven Presnell for the miR-181a luciferase promoter. We acknowledge the help from Cytometry & Imaging Microscopy Core Facility and the Athymic Animal and Preclinical Therapeutics Core of the Case Comprehensive Cancer Center ( P30CA043703 ). This work was supported by grants from The National Cancer Institute , R01CA197780 (A.D.), Department of Defense , OC150553 (A.D.), and The Young Scientist Foundation (A.D.). Funding Information: We thank Norma C. and Albert I. Geller for their constant support of the Gynecological Cancer Translational Research Program at Case Western Reserve University (A.D.). In addition, we thank Dr. Anirban Mitra for the HEYA8 cells, Dr. Goutham Narla for the MDA-MB-231 and H358 cells, and Dr. Steven Presnell for the miR-181a luciferase promoter. We acknowledge the help from Cytometry & Imaging Microscopy Core Facility and the Athymic Animal and Preclinical Therapeutics Core of the Case Comprehensive Cancer Center (P30CA043703). This work was supported by grants from The National Cancer Institute, R01CA197780 (A.D.), Department of Defense, OC150553 (A.D.), and The Young Scientist Foundation (A.D.). Publisher Copyright: {\textcopyright} 2018 The Authors",

year = "2019",

month = jan,

day = "8",

doi = "10.1016/j.stemcr.2018.12.002",

language = "English",

volume = "12",

pages = "122--134",

journal = "Stem Cell Reports",

issn = "2213-6711",

publisher = "Cell Press",

number = "1",

}

Belur Nagaraj, A, Joseph, P, Ponting, E, Fedorov, Y, Singh, S, Cole, A, Lee, W, Yoon, E, Baccarini, A, Scacheri, P, Buckanovich, R, Adams, DJ, Drapkin, R, Brown, BD & DiFeo, A 2019, 'A miRNA-Mediated Approach to Dissect the Complexity of Tumor-Initiating Cell Function and Identify miRNA-Targeting Drugs', Stem Cell Reports, vol. 12, no. 1, pp. 122-134. https://doi.org/10.1016/j.stemcr.2018.12.002

TY - JOUR

T1 - A miRNA-Mediated Approach to Dissect the Complexity of Tumor-Initiating Cell Function and Identify miRNA-Targeting Drugs

AU - Belur Nagaraj, Anil

AU - Joseph, Peronne

AU - Ponting, Erin

AU - Fedorov, Yuriy

AU - Singh, Salendra

AU - Cole, Alex

AU - Lee, Woncheol

AU - Yoon, Euisik

AU - Baccarini, Alessia

AU - Scacheri, Peter

AU - Buckanovich, Ronald

AU - Adams, Drew J.

AU - Drapkin, Ronny

AU - Brown, Brian D.

AU - DiFeo, Analisa

N1 - Funding Information: We thank Norma C. and Albert I. Geller for their constant support of the Gynecological Cancer Translational Research Program at Case Western Reserve University (A.D.). In addition, we thank Dr. Anirban Mitra for the HEYA8 cells, Dr. Goutham Narla for the MDA-MB-231 and H358 cells, and Dr. Steven Presnell for the miR-181a luciferase promoter. We acknowledge the help from Cytometry & Imaging Microscopy Core Facility and the Athymic Animal and Preclinical Therapeutics Core of the Case Comprehensive Cancer Center ( P30CA043703 ). This work was supported by grants from The National Cancer Institute , R01CA197780 (A.D.), Department of Defense , OC150553 (A.D.), and The Young Scientist Foundation (A.D.). Funding Information: We thank Norma C. and Albert I. Geller for their constant support of the Gynecological Cancer Translational Research Program at Case Western Reserve University (A.D.). In addition, we thank Dr. Anirban Mitra for the HEYA8 cells, Dr. Goutham Narla for the MDA-MB-231 and H358 cells, and Dr. Steven Presnell for the miR-181a luciferase promoter. We acknowledge the help from Cytometry & Imaging Microscopy Core Facility and the Athymic Animal and Preclinical Therapeutics Core of the Case Comprehensive Cancer Center (P30CA043703). This work was supported by grants from The National Cancer Institute, R01CA197780 (A.D.), Department of Defense, OC150553 (A.D.), and The Young Scientist Foundation (A.D.). Publisher Copyright: © 2018 The Authors

PY - 2019/1/8

Y1 - 2019/1/8

N2 - In this article, DiFeo and colleagues have utilized a miRNA 3′ UTR biosensor to study tumor-initiating cells in ovarian cancer and develop a high-throughput platform to uncover miRNA-targeting drugs. They have identified miR-181a as a potent driver of tumor initiation, which can be regulated by BET inhibitors, thus introducing a previously unknown biomarker for these drugs.

AB - In this article, DiFeo and colleagues have utilized a miRNA 3′ UTR biosensor to study tumor-initiating cells in ovarian cancer and develop a high-throughput platform to uncover miRNA-targeting drugs. They have identified miR-181a as a potent driver of tumor initiation, which can be regulated by BET inhibitors, thus introducing a previously unknown biomarker for these drugs.

UR - http://www.scopus.com/inward/record.url?scp=85058776577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058776577&partnerID=8YFLogxK

U2 - 10.1016/j.stemcr.2018.12.002

DO - 10.1016/j.stemcr.2018.12.002

M3 - Article

C2 - 30629937

AN - SCOPUS:85058776577

VL - 12

SP - 122

EP - 134

JO - Stem Cell Reports

JF - Stem Cell Reports

SN - 2213-6711

IS - 1

ER -

A miRNA-Mediated Approach to Dissect the Complexity of Tumor-Initiating Cell Function and Identify miRNA-Targeting Drugs

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this